Harrow Launches Affordability Initiative to Improve Eyecare Access and Reduce Patient Costs

Harrow Enhances Patient Access to Eyecare Through New Affordability Initiative

Harrow, a leading North American eyecare pharmaceutical company, introduces an innovative Access and Affordability Program, designed to improve the accessibility and affordability of its ophthalmic products. This program kicks off with targeted price reductions for some of Harrow’s most sought-after medications, including VIGAMOX® and MAXIDEX®. With these adjustments, the company aims to dismantle the financial obstacles that many patients face in obtaining essential eyecare treatments, ultimately enhancing patient outcomes and quality of life. As the pharmaceutical landscape becomes increasingly complex, this initiative signifies Harrow's commitment to patient-centric solutions.

In conjunction with the price reductions, Harrow forms a strategic partnership with GoodRx, a prominent prescription savings platform in the United States. This collaboration enables patients to access discounts on select products, such as FLAREX®, ILEVRO®, and VIGAMOX®, particularly benefiting those who lack sufficient insurance coverage. Mark L. Baum, Harrow’s Chairman and CEO, underscores the significance of this partnership, which provides an alternative cash-pay option for patients, allowing for broader access to necessary medications. The integration of GoodRx's services into Harrow's offerings enhances convenience, as patients can easily obtain their discounts through the GoodRx website or mobile app.

Harrow's initiatives are rooted in its founding mission to assist patients in managing and preserving their sight. CEO Mark L. Baum emphasizes that the high co-payments often associated with insurance plans can render crucial medications unaffordable. The company's new pricing strategy, coupled with the collaboration with GoodRx, represents a significant advancement toward fulfilling its mission, benefiting both patients and shareholders alike. By making its innovative portfolio more accessible, Harrow not only supports the eyecare professionals dedicated to preserving sight but also affirms its role as a pivotal player in the eyecare pharmaceutical industry.

In addition to the affordability program, Harrow recently reported impressive financial results for the third quarter, showcasing a 44% increase in revenue compared to the same period last year. The ongoing commitment to patient accessibility is crucial as the company continues to navigate its growth trajectory in a competitive market. Harrow's focus on affordability aligns with broader industry trends aimed at reducing costs and improving access to healthcare solutions, particularly in the realm of ophthalmic care.

This new initiative marks a vital step in Harrow's journey to address the challenges faced by patients in accessing sight-saving treatments, reinforcing its dedication to enhancing patient care within the eyecare industry.